Reporting on the Corporatization of Psychedelics
Psychedelics are where cannabis was a decade ago. In May, Denver became the first city to decriminalize psilocybin. Less than a month later, Oakland followed, decriminalizing all naturally-occurring psychedelics (i.e. all psychoactive or entheogenic plants). Now, more than 55 cities want to replicate that initiative. Federally, MDMA and psilocybin are projected to be legal for prescription by 2021. With the rapid progress, an industry is emerging, backed by major venture capitalists like Peter Thiel and Michael Novogratz. As investigative reporters with bylines in Rolling Stone, VICE, and Quartz, among others, we've started the first media company devoted to covering this fast-growing industry and holding those at the forefront of it accountable for making psychedelic medicine accessible.
Share this idea
Additional Supporting Materials
- The latest on psychedelic policy and research. The promise—and limitations—psychedelics are showing for mental health, from PTSD to depression.
- How cannabis paved the way for psychedelics; How for-profit interests threaten the equity of both industries and what they can learn from one another
- The accessibility of psychedelic medicine now (ayahuasca ceremonies in the Amazon, ibogaine clinics in Mexico) and how people can participate safely.
Shelby Hartman, Editor-In-Chief, DoubleBlind